09.02.2010 • NewsformalinLanxessunder construction

Lanxess to Build New Formalin Facility At Its Krefeld-Uerdingen Site

Lanxess plans to build a new facility for formalin production at its site in Krefeld-Uerdingen. The specialty chemicals group will then no longer be dependent on buying in the feedstock, which it needs for the production of trimethylolpropane (TMP).

The total investment for the new building and the process optimization will be in the order of €18 million. As a result, Lanxess will create five additional jobs at its Krefeld-Uerdingen site. Construction of the new plant is expected to begin in the third quarter of this year, with commissioning earmarked for the end of 2011. In addition to the production facility, new formalin and methanol tanks will also be installed across an area measuring around 1,000 m2.

Clear 'Thumbs-Up' For Germany as An Industrial Location

"With our own formalin plant, we will be able to further expand our strong global position as a manufacturer and supplier of trimethylolpropane," said Werner Breuers, member of the board of management of Lanxess. "The elimination of transport costs combined with various synergy effects with regard to energy efficiency will give us significant cost benefits."

Rainier van Roessel, member of the board of management and Labor Relations Director of Lanxess, said: "This investment by the Basic Chemicals business unit sends out another important signal in favor of Germany as a location for industrial production, and is a clear thumbs-up for our site in Krefeld-Uerdingen."

The business unit had announced last year that it would complete the expansion of the production facilities for the key basic chemicals cresols, Vulkanox BHT, Vulkanox BKF and monochlorobenzene at the Leverkusen site in the first quarter of 2010. The project, costing around €35 million, will raise capacities by up to 60%.

Lanxess will continue to back the German production facilities, according to van Roessel. "Well-trained, experienced employees, an excellent infrastructure and direct access to technical and scientific innovation are very important competitive advantages and a definite benefit for the Uerdingen site." Only two weeks ago, following the official groundbreaking ceremony, Lanxess began construction of a new plant for membrane technology in Bitterfeld in the eastern part of Germany. It will cost €30 million. The specialty chemicals company plans to invest some €150 million at its German sites this year.

Company

Logo:

LANXESS Deutschland GmbH

Kennedyplatz 1
50569 Köln
Germany

Company contact







Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
24.01.2025 • News

CEFIC Publishes 2024 Facts and Figures Report

CEFIC , the European Chemical Industry Council, has published its 2024 Facts & Figures report, which reinforces the need to take bold and urgent action to secure Europe’s industrial future, not only to implement the Green Deal but also to prevent further de-industrialization in Europe.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.